Ernexa Therapeutics Inc. Subscription and Circulation Revenue (Deprecated 2018-01-31)
Ernexa Therapeutics Inc. (ERNA) reported Subscription and Circulation Revenue (Deprecated 2018-01-31) of $4.07 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Income Statement › Other Income
us-gaap:SubscriptionRevenue · last filed 2018-05-11
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $4.07M, a 3.81% decline year-over-year.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $4.21M, a 3.31% decline year-over-year.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $4.28M, a 2.26% decline year-over-year.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $4.23M, a 2.82% decline year-over-year.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for fiscal 2017 was $16.95M, a 2.94% decline from fiscal 2016.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for fiscal 2016 was $17.46M, a 2.35% increase from fiscal 2015.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for fiscal 2015 was $17.06M, a 5.23% decline from fiscal 2014.
- Ernexa Therapeutics Inc. subscription and circulation revenue (deprecated 2018-01-31) for fiscal 2014 was $18.00M, a 9.11% decline from fiscal 2013.
| Period end | Subscription and Circulation Revenue (Deprecated 2018-01-31) 3 month | Subscription and Circulation Revenue (Deprecated 2018-01-31) 6 month | Subscription and Circulation Revenue (Deprecated 2018-01-31) 9 month | Subscription and Circulation Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $4.07M 10-Q · filed 2018-05-11 | $8.28M derived: sum of 2 quarters · filed 2018-05-11 | $12.56M derived: sum of 3 quarters · filed 2018-05-11 | $16.79M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $8.49M derived: sum of 2 quarters · filed 2018-03-09 | $12.72M derived: sum of 3 quarters · filed 2018-03-09 | $16.95M 10-K · filed 2018-03-09 |
| 2017-09-30 | $4.28M 10-Q · filed 2017-11-08 | $8.51M derived: sum of 2 quarters · filed 2017-11-08 | $12.74M 10-Q · filed 2017-11-08 | $17.09M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-06-30 | $4.23M 10-Q · filed 2017-08-04 | $8.46M 10-Q · filed 2017-08-04 | $12.81M derived: sum of 3 quarters · filed 2018-05-11 | $17.19M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-03-31 | $4.23M 10-Q · filed 2018-05-11 | $8.58M derived: sum of 2 quarters · filed 2018-05-11 | $12.96M derived: sum of 3 quarters · filed 2018-05-11 | $17.32M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $4.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $8.73M derived: sum of 2 quarters · filed 2018-03-09 | $13.09M derived: sum of 3 quarters · filed 2018-03-09 | $17.46M 10-K · filed 2018-03-09 |
| 2016-09-30 | $4.38M 10-Q · filed 2017-11-08 | $8.73M derived: sum of 2 quarters · filed 2017-11-08 | $13.11M 10-Q · filed 2017-11-08 | $17.50M derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $4.36M 10-Q · filed 2017-08-04 | $8.73M 10-Q · filed 2017-08-04 | $13.12M derived: sum of 3 quarters · filed 2017-08-04 | $17.39M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | $4.37M 10-Q · filed 2017-05-04 | $8.77M derived: sum of 2 quarters · filed 2017-05-04 | $13.03M derived: sum of 3 quarters · filed 2017-05-04 | $17.24M derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $8.66M derived: sum of 2 quarters · filed 2017-03-09 | $12.86M derived: sum of 3 quarters · filed 2017-03-09 | $17.06M 10-K · filed 2017-03-09 |
| 2015-09-30 | $4.27M 10-Q · filed 2016-11-09 | $8.47M derived: sum of 2 quarters · filed 2016-11-09 | $12.67M 10-Q · filed 2016-11-09 | $17.06M derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $4.20M 10-Q · filed 2016-08-04 | $8.40M 10-Q · filed 2016-08-04 | $12.79M derived: sum of 3 quarters · filed 2016-08-04 | $17.21M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $4.20M 10-Q · filed 2016-05-09 | $8.59M derived: sum of 2 quarters · filed 2016-05-09 | $13.01M derived: sum of 3 quarters · filed 2016-05-09 | $17.58M derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $8.81M derived: sum of 2 quarters · filed 2016-03-15 | $13.38M derived: sum of 3 quarters · filed 2016-03-15 | $18.00M 10-K · filed 2016-03-15 |
| 2014-09-30 | $4.42M 10-Q · filed 2015-11-09 | $9.00M derived: sum of 2 quarters · filed 2015-11-09 | $13.62M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $4.57M 10-Q · filed 2015-08-10 | $9.19M 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $4.62M 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | $19.81M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |